Related Experiment Video

Updated: Jun 21, 2026

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme
04:17

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme

Published on: September 27, 2024

Albumin from human serum does not contain asymmetric dimethylarginine (ADMA)

Dimitrios Tsikas, Bibiana Beckmann

    Clinical Biochemistry
    |August 8, 2009
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Consensus Brain-derived Protein, Extraction Protocol for the Study of Human and Murine Brain Proteome Using Both 2D-DIGE and Mini 2DE Immunoblotting10:51

    Consensus Brain-derived Protein, Extraction Protocol for the Study of Human and Murine Brain Proteome Using Both 2D-DIGE and Mini 2DE Immunoblotting

    Published on: April 10, 2014

    Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples13:21

    Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples

    Published on: May 4, 2012

    Related Concept Videos

    Drug Distribution: Plasma Protein Binding01:29

    Drug Distribution: Plasma Protein Binding

    Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
    Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

    Factors Affecting Protein-Drug Binding: Patient-Related Factors

    Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
    Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
    Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

    Factors Affecting Protein-Drug Binding: Protein-Related Factors

    Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
    The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
    Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

    Factors Affecting Protein-Drug Binding: Drug-Related Factors

    Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
    One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...